

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.		APPLICATION NO.	
				4821-411		To Be Assigned	
				APPLICANT			
				J. YOUNG et al.			
FILING DATE				GROUP			
January 29, 2001				To Be Assigned			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	CLASS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
					SS	SS	IF APPROPRIATE
	AA	6,127,363	10/2000	Doherty et al.	514	220	
	AB	5,795,880	08/1998	Svec et al.	514	169	
	AC	5,780,051	07/1998	Eswara et al.	424	449	
	AD	5,733,566	03/1998	Lewis	424	426	
	AE	5,719,283	02/1998	Bell et al.	544	262	
	AF	5,674,553	10/1997	Shinoda et al.	427	68	
	AG	5,639,476	06/1997	Oshlack et al.	424	468	
	AH	5,591,767	01/1997	Mohr et al.	514	413	
	AI	5,552,429	09/1996	Wong et al.	514	415	
	AJ	5,459,164	10/1995	Vargas	514	646	
	AK	5,436,272	07/1995	Scheinbaum	514	646	
	AL	5,354,556	10/1994	Sparks et al.	424	419	
	AM	5,250,534	10/1993	Bell et al.	514	258	
	AN	5,120,548	06/1992	McClelland et al.	424	473	
	AO	5,104,899	04/1992	Young et al.	514	646	
	AP	5,073,543	12/1991	Marshall et al.	514	21	
	AQ	5,068,440	11/1991	Jeffery et al.	564	442	
	AR	5,059,595	10/1991	Le Grazie	424	468	
	AS	4,988,814	01/1991	Abou-Gharbia et al.	544	295	
	AT	4,939,175	07/1990	Ukai et al.	514	646	
	AU	4,929,629	05/1990	Jeffery	514	646	
	AV	4,871,774	10/1989	Rees	514	646	
	AW	4,816,488	03/1989	Rees	514	646	
	AX	4,814,352	03/1989	Jeffery et al.	514	646	
	AY	4,806,570	02/1989	Jeffery et al.	514	646	
	AZ	4,746,680	05/1988	Jeffery et al.	514	646	
	BA	4,552,828	11/1985	Toya et al.	430	217	
	BB	4,522,828	06/1985	Jeffery et al.	514	646	
	BC	4,008,719	02/1977	Theeuwes et al.	128	260	
	BD	3,960,891	06/1976	Malen et al.	260	327	
	BE	3,916,899	11/1975	Theeuwes et al.	128	260	
	BF	3,845,770	11/1974	Theeuwes et al.	128	260	
	BG	3,598,123	08/1971	Zaffaroni	128	268	

	BH	3,536,809	10/1970	Applezweig	424	28	
	BI	3,471,515	10/1969	Troxler et al.	260	326.15	
	BJ	3,155,670	11/1964	Janssen et al.	260	294	
	BK	3,155,669	11/1964	Janssen et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
			E		SS	LASS	YES NO
	BL	WO 99/33450	07/1999	PCT (in English)			
	BM	WO 98/13034	04/1998	PCT (in English)			
	BN	WO 98/13033	04/1998	PCT (in English)			
	BO	WO 98/11884	03/1998	PCT (in English)			
	BP	WO 98/06722	02/1998	PCT			X <sub>(abs)</sub>
	BQ	EP 0 781 561 A1	07/1997	EPO (in English)			
	BR	WO 97/20810	06/1997	PCT (in English)			
	BS	WO 97/03675	02/1997	PCT (in English)			
	BT	WO 95/21615	08/1995	PCT (in English)			
	BU	WO 95/20949	08/1995	PCT (in English)			
	BV	WO 94/28902	12/1994	PCT (in English)			
	BW	WO 94/00114	01/1994	PCT (in English)			
	BX	WO 94/00047	01/1994	PCT (in English)			
	BY	WO 90/06110	06/1990	PCT (in English)			
	BZ	WO 88/06444	09/1988	PCT (in English)			
	CA	DE 32 12 682 A1	10/1982	Germany			X <sub>(abs)</sub>
	CB	GB 2098602 A	11/1982	United Kingdom			
	CC	EP 0 035 597	9/1981	Europe			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
—	CD	Baldessarini et al., <i>Life Sciences</i> 39: 1765-1777, (1986).					
—	CE	Buckett et al., "BTS 54 524-An Approach to Rapidly Acting Antidepressant," <i>New Concepts in Depression</i> 2: 167-172 (1988).					
—	CF	Buckett et al., "The Pharmacology of Sibutramine Hydrochloride (BTS 54 524), A New Antidepressant which induces Rapid Noradrenergic Down-Regulation", <i>Prog. Neuro-Psychopharmacol. &amp; Biol. Psychiat.</i> 12: 575-584 (1988).					
	CG	Buckett et al., "Sibutramine Hydrochloride," <i>Drugs of the Future</i> 13(8): 736-738 (1988).					
—	CH	Butler, D., <i>Facile Cycloalkylation of Arylacetonitriles in Dimethyl Sulfoxide</i> , <i>J. Org. Chem.</i> , 36:1308-1309 (1971)					
—	CI	Canonne, P., et al., <i>Effet du Benzene Dans la Reaction de Grignard sur les Nitriles</i> , <i>Tetrahedron Lett.</i> , 21:155-58 (1980)					
—	CJ	Carstensen, J., <i>Drug Stability: Principles &amp; Practice</i> , 2d. Ed., pp. 379-80, Marcel Dekker, NY, NY, (1995).					
—	CK	Castello, R.A., et al., <i>Discoloration of Tablets Containing Amines and Lactose</i> , <i>Pharm. Sci.</i> 51(2):106-108 (1962)					
—	CL	Cheetham, S.C., et al., [ <sup>3</sup> H]Paroxetine Binding in Rat Frontal Cortex Strongly Correlates with [ <sup>3</sup> H]5-HT Uptake: Effect of Administration of Various Antidepressant Treatments, <i>Neuropharmacology</i> (1993), 32(8), 737-743					
—	CM	Cliffe et al., (S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: A Selective Antagonist at Presynaptic and Postsynaptic 5-HT <sub>1A</sub> Receptors, <i>Med. Chem.</i> , 36:1509-1510 (1993)					
—	CN	<i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fourth Ed., American Psychiatric Association, (1997).					
—	CO	<i>Diagnostic and Statistical Manual of Mental Disorders</i> , 3rd Ed., American Psychiatric Association (1981).					
—	CP	Dreshfield et al., <i>Enhancement of Fluoxetine-Dependent Increase of Extracellular Serotonin (5-HT) Levels by (-)-Pindolol, an Antagonist at 5-HT<sub>1A</sub> Receptors</i> , <i>Neurochem. Res.</i> , 21(5):557-562 (1996)					
—	CQ	Eliel, E.L., <i>Stereochemistry of Carbon Compounds</i> (McGraw-Hill, NY, 1962).					

1	CR	Evans et al., "Prevalence of Alzheimer's Disease in a Community Population of Older Persons," J.A.M.A. 262: 2551-2556 (1989).
1	CS	Fuentes, J. et al., "Comparison of the apparent anti-depressant activity of (-) and (+) tranylpromine in an animal model", Chemical Abstracts, 85: 7, page 31, No. 40768t (1976).
1	CT	Goodman & Gilman, The Pharmacological Basis of Therapeutics, 362-373, 404 (9 <sup>th</sup> ed. McGraw-Hill, 1996)
1	CU	Gray et al., The Involvement of the Opioidergic System in the Antinociceptive Mechanism of Action of Antidepressant Compounds, BR.J. Pharmacol., Vol. 124, No. 4, (1998) pp 669-674
1	CV	Handbook of Pharmaceutical Excipients, 2 <sup>nd</sup> ed., Wade and Willer eds., pp. 257-259 (1994)
1	CW	Heal et al., A Comparison of the Effects on Central 5-HT Function of Sibutramine Hydrochloride and Other Weight-Modifying Agents, BR.J. Pharmacol. (1998), 125(2), 301-308
1	CX	Hillyer et al., (S)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetraxil: A Putative 5-HT <sub>1A</sub> Receptor Antagonist, J. Med. Chem., 33:1541-44 (1990)
1	CY	J. Med. Chem., Vol. 36, No. 17, 2540 (1993)
1	CZ	Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985).
1	DA	Jacques et al., "Enantiomers, Racemates and Resolutions," (Wiley-Interscience, NY, 1981).
1	DB	Jamali et al., Journal of Pharmaceutical Sciences, 78: 9: 695-715 (1989)
1	DC	Jeffery et al., Synthesis of Sibutramine, A Novel Cyclobutylalkylamine Useful in the Treatment of Obesity, and its Major Human Metabolites, J. Chem. Soc. Perkin. Trans. 1, 2583-2589 (1996)
1	DD	King et al., "Clinical Pharmacology of Sibutramine Hydrochloride (BTS 54524) A New Antidepressant, in Healthy Volunteers," Clinical Pharmac. 26: 607-611 (1989).
1	DE	Kula et al., "Effects of N-Substituted Phenyltetrahydropyridines on Cerebral High-Affinity Synaptosomal Uptake of Dopamine and Other Monoamines in Several Mammalian Species," Life Sciences 34(26): 2567-2575, (1984).
1	DF	Luscombe et al., The Contribution of Metabolites to the Rapid and Potent Down-Regulation of Rat Cortical $\beta$ -Adrenoceptors by the Putative Antidepressant Sibutramine Hydrochloride, Neuropharmacology, Vol. 28, No. 2, (1989) pp 129-134
1	DG	The Merck Manual of Diagnosis and Therapy, 17th Ed., Merck & Co., Inc., Whitehouse Station, NJ, (1999).
1	DH	Middlemiss et al., Centrally Active 5-HT Receptor Agonists and Antagonists, Neurosci. and Biobehv. Rev., 16:75-82 (1992)
1	DI	Moreau et al., Behavioral Profile of the 5-HT <sub>1A</sub> Receptor Antagonist (S)-UH-301 in Rodents and Monkeys, Brain Res. Bull., 29:901-04 (1992)
1	DJ	Nakada et al., An Enantioconvergent Route to (-)-Kainic Acid, Tetrahedron Lett., 38:857-860 (1997)
	DK	Physician's Desk Reference® 473-475 (53 <sup>rd</sup> ed., 1999)
	DL	Physician's Desk Reference® 475-476 (53 <sup>rd</sup> ed., 1999)
	DM	Physician's Desk Reference® 764-766 (53 <sup>rd</sup> ed., 1999)
	DN	Physician's Desk Reference® 823-825 (53 <sup>rd</sup> ed., 1999)
	DO	Physician's Desk Reference® 978-979 (53 <sup>rd</sup> ed., 1999)
	DP	Physician's Desk Reference® 1054-1056 (53 <sup>rd</sup> ed., 1999)
	DQ	Physician's Desk Reference® 1332-1334 (53 <sup>rd</sup> ed., 1999)
	DR	Physician's Desk Reference® 1369-1370 (53 <sup>rd</sup> ed., 1999)
	DS	Physician's Desk Reference® 1432-1436 (53 <sup>rd</sup> ed., 1999)
	DT	Physician's Desk Reference® 1494-1498 (53 <sup>rd</sup> ed., 1999)
	DU	Physician's Desk Reference® 1641-1645 (53 <sup>rd</sup> ed., 1999)
	DV	Physician's Desk Reference® 2004-2009 (53 <sup>rd</sup> ed., 1999)
	DW	Physician's Desk Reference® 2075-2078 (53 <sup>rd</sup> ed., 1999)
	DX	Physician's Desk Reference® 2190-2192 (53 <sup>rd</sup> ed., 1999)
	DY	Physician's Desk Reference® 2367-2368 (53 <sup>rd</sup> ed., 1999)
	DZ	Physician's Desk Reference® 2396-2399 (53 <sup>rd</sup> ed., 1999)
	EA	Physician's Desk Reference® 2490-2493 (53 <sup>rd</sup> ed., 1999)
	EB	Physician's Desk Reference® 2516-2521 (53 <sup>rd</sup> ed., 1999)
	EC	Physician's Desk Reference® 2688-2691 (53 <sup>rd</sup> ed., 1999)
	ED	Physician's Desk Reference® 2701-2704 (53 <sup>rd</sup> ed., 1999)
	EE	Physician's Desk Reference® 2720-2726 (53 <sup>rd</sup> ed., 1999)
	EF	Physician's Desk Reference® 2735-2736 (53 <sup>rd</sup> ed., 1999)

	EG	Physician's Desk Reference® 2886-2888 (53 <sup>rd</sup> ed., 1999)
	EH	Physician's Desk Reference® 2908-2910 (53 <sup>rd</sup> ed., 1999)
	EI	Physician's Desk Reference® 3092-3094 (53 <sup>rd</sup> ed., 1999)
	EJ	Physician's Desk Reference® 3101-3104 (53 <sup>rd</sup> ed., 1999)
	EK	Physician's Desk Reference® 3224-3225 (53 <sup>rd</sup> ed., 1999)
	EL	Physician's Desk Reference® 3267-3272 (53 <sup>rd</sup> ed., 1999)
	EM	Physician's Desk Reference® 3307-3309 (53 <sup>rd</sup> ed., 1999)
	EN	Physician's Desk Reference® 3383-3384 (53 <sup>rd</sup> ed., 1999)
	EO	Physician's Desk Reference® 2520 (52 <sup>nd</sup> ed., 1998)
	EP	Physician's Desk Reference® 2958 (52 <sup>nd</sup> ed., 1998)
—	EQ	Remington's: The Practice of The Science and Pharmacy, 19 <sup>th</sup> ed., Gennaro, ed., p. 1625 (1995)
—	ER	Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).
—	ES	Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing, Easton PA (1980).
—	ET	Stock, M.J., Sibutramine: A Review of the Pharmacology of a Novel Anti-Obesity Agent, Int'l J. Obesity, 21(Supp. 1):S25-S29 (1997)
—	EU	U.S. Pharmacopia (USP) SP (XXI)/NF (XVI)
—	EV	Wilen et al., Tetrahedron, 2725-36 33(21) (1977).
—	EW	Wilen, S.H., Tables of Resolving Agents and Optical Resolutions 268 (E.L. Eliel ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972).
EXAMINER		DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		